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The aim of the present study was to investigate the relationship between 
the expression of iNOS, COX-2 and VEGF mRNA levels and malignancy degree 
in canine malignant mammary tumours. Thirty-five bitches presented with the 
complaint of mammary masses, aged 6–10 years and representing different breeds, 
were used. The expressions of iNOS, COX-2 and VEGF mRNA levels were sig-
nificantly higher in both benign and malignant tumours than in the adjacent non-
neoplastic mammary glands (P < 0.05). The iNOS, COX-2 and VEGF mRNA ex-
pression levels of grade 2 tumours were higher than those of grade 1 tumours; 
however, the highest expression levels were detected in grade 3 tumours. Thus, 
increased iNOS, COX-2 and VEGF gene mRNA levels were found to be related 
with the histological grade of malignancy in dogs with mammary tumours. 
Key words: Canine mammary tumour, gene expression, iNOS, COX-2, 
VEGF 
Mammary tumours are the most common neoplasms in the female dog 
(Johnston et al., 2001), and both benign and malignant tumours are diagnosed 
with equal frequency (Moulton, 1990). Prognostic factors for canine mammary 
tumour (CMT) are related to its malignant histological characteristics. According 
to the criteria, the therapy dose and the animal’s survival are determined on the 
basis of predictive factors such as metastasis (Cianfrocca and Goldstein, 2004; 
Karayannopoulou et al., 2005). 
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Cyclooxygenases, especially COX-2, are implicated in tumour development 
and progression in human breast cancer (Howe, 2007). Similarly, the expression 
of COX-2 was demonstrated to be more frequent and more intense in malignant 
CMT than in benign tumours, suggesting its role in tumourigenesis (Dore et al., 
2003). Additionally, a correlation was shown between COX-2 expression and 
more aggressive tumour phenotype (Guimaraes et al., 2014). It has been noticed 
that COX-2 may play a direct role in tumour cell growth through an antiapop-
totic pathway and thus regulate tumour expansion indirectly in humans (Wil-
liams et al., 1999). 
Neoplastic cells undergo genetic changes and acquire the ability to create 
their capillary blood supply in order to provide nourishment and oxygen for new 
cell growth, thus resulting in larger tumours (Villalobos and Kaplan, 2007). Vas-
cular endothelial growth factor (VEGF) is the most important tumour angiogene-
sis factor which stimulates endothelial cell proliferation, leads to the formation of 
new blood vessels and regulates vascular permeability (Restucci et al., 2002; 
Queiroga et al., 2010). Furthermore, it has been determined that VEGF secretion 
in the stromal cells of tumours is caused by prostaglandins (Bing et al., 2001). 
COX-2 leads to tumour progression through the level of invasion, angiogenesis, 
metastasis and the inhibition of apoptosis (Heller et al., 2005). In addition, it has 
been shown that increased COX-2 expression was not significantly correlated 
with elevated VEGF expression as well as age, histologic type and tumour size in 
canine invasive mammary carcinomas (Millanta et al., 2006), whereas its expres-
sion was significantly correlated with poorer prognosis (Queiroga et al., 2010) 
and histological type of CMTs (Queiroga et al., 2011). 
Nitric oxide (NO) is produced from L-arginine by nitric oxide synthases 
(NOS) such as neuronal NOS, endothelial NOS (eNOS) and inducible NOS (iNOS) 
(Förstermann et al., 1994). Endothelial NOS and neuronal NOS are expressed 
fundamentally in neurons and endothelial cells where their activation depends on 
calcium and calmodulin, whereas iNOS is expressed in macrophages, neutrophils, 
hepatocytes, cardiac myocytes, chondrocytes and various neoplastic diseases 
(Knowles and Moncada, 1994; Thomsen et al., 1995; Lechner et al., 2005). The 
role of NO in tumour cell apoptosis and survival depends on the cell type, the 
concentration and the time of cellular exposure to NO. Accordingly, the induc-
tion of apoptosis requires high levels of NO, particularly produced in the pres-
ence of iNOS (Lala and Chakraborty, 2001). Several studies have shown that the 
expression of iNOS in mammary tumours is correlated with angiogenesis and 
degree of malignancy in cats and humans (Vakkala et al., 2000; Islam et al., 
2012). Islam et al. (2012) suggested that iNOS might be an immunohistochemi-
cal marker to detect the degree of malignancy in feline mammary carcinoma. 
The aim of the present study was to investigate the relationship between 
the expression of iNOS, COX-2 and VEGF mRNA levels and the degree of ma-
lignancy in canine malignant mammary tumours, and to compare these expres-
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sions with those in clinically healthy mammary glands on the same mammary 
chain. To the best of our knowledge, this is the first study on the relationship be-
tween the expression of iNOS and malignancy degree in canine malignant 
mammary tumours. 
 
Materials and methods 
Animals  
A total of 35 bitches (aged 6–10 years and representing different breeds) 
brought to the Clinic of Obstetrics and Gynaecology, Veterinary Faculty of the 
University of Ankara and University of Ondokuz Mayis with the complaint of 
mammary masses were used in the study. Animals with distant metastases and 
suspected inflammatory mammary carcinomas were not included. The surgical 
techniques included regional mastectomy as well as unilateral or bilateral com-
plete mastectomy depending on the clinical stage and the number of tumours in 
the mammary gland chain. Malignant tumours were compared with adjacent 
non-neoplastic mammary glands of the dogs (NMGs) (n = 8). The study was per-
formed according to the principles outlined in Decision No. 2014/8 of the Ethics 
Committee of Animal Research of Turkey. 
Clinical and histopathological analysis 
Before starting the study, a complete physical examination was done for 
all animals. All mammary glands and regional lymph nodes (axillary and inguinal) 
were examined. Thoracic radiographs (right and left lateral, ventrodorsal) were 
taken and abdominal ultrasonographic examination was performed to determine 
the presence of metastasis. In addition, the number of tumours per animal, loca-
tion, adherence to skin, adherence to underlying tissues, and tumour ulceration 
were recorded. The date of first presentation and the growth rate of the tumours 
(defined as slow, medium or fast) were also recorded based upon the history 
(Perez Alenza et al., 1997; Queiroga et al., 2005). 
Mammary tissues were fixed in 10% formalin solution, embedded in paraf-
fin, and then 5-µm histological sections were made and stained with haematoxy-
lin and eosin (HE). Tumours were classified by size (in centimetres; wide-large-
high as diameter), according to the World Health Organization Clinical Staging 
System TNM (Owen, 1980), as T1 (< 3 cm), T2 (3–5 cm) and T3 (> 5 cm). In cases 
of multiple tumours, the largest one was used as the basis for classification. 
Histological diagnosis was made on the basis of Goldschmidt’s classifica-
tion updated in recent years for CMTs as described by Goldschmidt et al. (2011). 
Histological grading of mammary tumours was performed according to the Not-
tingham grading system, which belongs to the Elston-Ellis modification of the 
original Scarff-Bloom-Richardson (SBR) grading system and is popularly known 
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as the contemporary European Breast Cancer Grading System. This system is 
based on three morphological features: tubule formation, mitotic index and nu-
clear pleomorphism (Simpson et al., 2000). Scoring was obtained by screening 
10 microscopic areas at ×400 magnification (High Power Field) at the periphery 
of the tumour. Up to 9 mitoses per 10 fields were scored 1 point, 10–19 mitoses 
2 points, and 20 or more mitoses 3 points. At the same time, tubule formation 
was evaluated as follows: majority of the tumour (> 75%), moderate degree (10–
75%) and little or none (< 10%). Depending on the nuclear polymorphism, the 
cell characteristics were scored as follows: small regular uniform cells: 1 point; 
moderate nuclear size and variation: 2 points; marked nuclear variation: 3 points. 
Overall, Grade 1 (G1) represented well-differentiated tumours of 3–5 points, 
Grade 2 (G2) moderately differentiated tumours of 6–7 points, and Grade 3 (G3) 
poorly differentiated tumours of 8–9 points (Elston and Ellis, 1998; Simpson et 
al., 2000). Additionally, in the differentiation of benign and malignant mammary 
tumours necrosis, invasion to periphery of tumour and lymphatics, and metasta-
sis to regional lymph node were considered. 
Total RNA isolation and reverse transcriptase (RT) reaction 
Total RNA was isolated from the mammary tissue samples of 35 bitches 
using Trizol reagent (peqGOLD TriFastTM, Peqlab, Erlangen, Germany) and 
subsequently treated with RNase-free DNase I recombinant to prevent genomic 
DNA contaminations (DNase I; Roche Diagnostics, Germany) according to the 
manufacturer’s instructions. RNA pellets were dissolved in 10–30 μl RNase- and 
DNase-free water, after which they were air-dried. The quantity and quality of 
total RNA were measured spectrophotometrically at 260 and 280 nm (NanoDrop 
2000, Thermo Scientific). Isolated RNA was then stored at –80 °C. Equal amounts 
of RNA were used for reverse transcription. Complementary DNA (cDNA) was 
synthesised from 1 µg isolated RNA from each sample using the Transcriptor 
First Strand cDNA Synthesis Kit (Roche Diagnostics, Germany) according to the 
manufacturer’s protocol, and synthesis reaction was carried out in an Eppendorf 
Mastercycler ep gradient S thermal cycler (Eppendorf, Hamburg, Germany). 
Samples were analysed in duplicates. cDNA products were kept at –20 °C. 
Quantitative real-time PCR analysis 
Real-time polymerase chain reaction (PCR) was performed using a 
LightCycler 480 instrument (Roche Diagnostics, Mannheim, Germany) accord-
ing to the manufacturer’s instructions. The expression levels of the following 
genes were investigated: iNOS, COX-2 and VEGF. Beta actin was used as a 
housekeeping gene in order to normalise the mRNA expression levels of target 
genes. Probes and primers spanning the exon–exon junction were designed for 
each gene assay using the online UPL Assay Design Center (http://www.roche-
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applied-science.com/sis/rtpcr/upl/index.jsp). The sequences of the gene-specific 
primers and the UPL numbers are presented in Table 1. A 2-μl volume of cDNA 
product was subjected to real-time PCR in a 10-μl total reaction mixture contain-
ing 2.5 μl of TaqMan Universal PCR Master Mix (Roche Diagnostics, Mann-
heim, Germany), 0.5 μl of sense and antisense primers, and 0.1 μl probe and 
template cDNA. Each sample was analysed in triplicate. 
Table 1 
Gene-specific primer and probe sequences 
Gene Forward primer Reverse primer 
UPL 
probe 
no. 
ACTB 5’-GATGTGGCTTCTTGGGTGTT-3’ 5’-CCAAGATAGGGACAGCTTGGT-3’ 43 
iNOS 5’-TTTCTGGGAGCATCACTCCT-3’ 5’-AAGGGGACAGGACATAATTTAACA-3’ 31 
COX-2 5’-TGCTTAAACAGGAGCATCCA-3’ 5’-TTAGCCTGCTCGTCTGGAAC-3’ 41 
VEGF 5′-CGTGCCCACTGAGGAGTT-3′ 5′-GCCTTGATGAGGTTTGATCC-3′ 9 
Statistical analysis 
The data were analysed using LightCycler Software v 3.5 (Roche Diag-
nostics). Relative mRNA expression of iNOS, COX-2 and VEGF were deter-
mined using Relative Expression Software Tool 2008 (REST©) (Pfaffl et al., 
2002). Correlations between the expression levels and the tumour grade were not 
determined because cycle threshold (Ct) values obtained from real-time PCR 
analysis resulted in real-time gene expression levels, and each animal had a sin-
gle Ct value. 
 
Results 
Histopathological findings 
Twenty-nine malignant mammary tumours and six benign mammary tu-
mours were diagnosed (Table 2). The commonest malignant tumour types in the 
study were carcinosarcoma (8/29; 27.58%) and mixed carcinoma (7/29; 24.13%). 
Clinically healthy mammary glands localised close to the gland with malignant 
tumour were evaluated and confirmed as non-neoplastic or healthy by histopa-
thological evaluation. The maximum diameters of the malignant mammary tu-
mours, histologic malignancy grades, tumour ulceration and necrosis, rate of 
growth and lymph node metastasis are presented in Table 3. 
The determination of histologic malignancy grade of the 29 dogs with ma-
lignant mammary tumours revealed that 12 had G1, 10 had G2 and 7 had G3 tu-
mours. Of the 13 dogs (3 had G1, 7 had G2 and 3 had G3) in which histopa-
thological lymph node examination was performed, lymph node metastasis was 
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found in 1 dog with G1, 2 dogs with G2 and 1 dog with G3. Tumour ulceration 
and necrosis were observed in 7 and 14 dogs, respectively (Table 3). 
Table 2 
Classification of canine mammary tumours (Goldschmidt et al., 2011) 
Histological type Number 
Malignant tumours 29 
Carcinosarcoma 8 
Mixed carcinoma 7 
Solid carcinoma 3 
Complex carcinoma 2 
Intraductal papillary carcinoma 2 
Tubulopapillary carcinoma 2 
Carcinoma in situ 1 
Squamous cell carcinoma 1 
Tubular carcinoma 1 
Spindle cell carcinoma 1 
Comedocarcinoma 1 
Benign tumours 6 
Benign mixed tumour  3 
Intraductal papillary adenoma  1 
Simple adenoma  1 
Adenomyoepithelioma 1 
Expression of iNOS, COX-2 and VEGF in canine mammary tumours 
The expression of iNOS, COX-2 and VEGF mRNA levels was signifi-
cantly increased (P < 0.05) in both benign and malignant tumours compared to 
adjacent non-neoplastic mammary glands (Fig. 1). In addition, the expressions 
were higher in malignant tumours than in benign tumours, although the differ-
ence was not statistically significant (P > 0.05). 
Association of iNOS, COX-2 and VEGF expressions with clinicopathological  
parameters 
Table 3 presents the association between iNOS, COX-2 and VEGF ex-
pressions and clinicopathological features in malignant tumours. iNOS, COX-2 
and VEGF expressions were associated with histological grade of malignancy 
and tumour growth rate (P < 0.05). The expressions of G1 tumours were not sta-
tistically different when compared to G2 (P > 0.05). On the other hand, the ex-
pression levels were higher in G3 tumours than in G1 tumours (P < 0.05) (Fig. 2). 
There was no statistically significant association (P > 0.05) between iNOS, 
COX-2 and VEGF mRNA expressions and tumour size (Fig. 3). 
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Table 3 
Association of clinicopathological features with iNOS, COX-2 and VEGF expression in malignant 
tumours 
COX-2 VEGF iNOS 
Variable 
n P n P n P 
Tumour size (cm)       
T1 (< 3 cm) 7  11  11  
T2 (3–5 cm) 11 0.271 11 0.214 11  
T3 (5 cm) 11 0.267 11 0.275 11 0.248 
Differentiation grade       
1 8  8  8  
2 8 0.165 8 0.105 8 0.172 
3 13 0.139 13 0.134 13 0.154 
Histological grade of malignancy       
Grade 1 12  12  12  
Grade 2 10 0.031* 10 0.044* 10 0.039* 
Grade 3 7 0.036* 7 0.038* 7 0.023* 
Ulceration       
Present 7  7  7  
Absent 22 0.235 22 0.179 22 0.215 
Necrosis       
Present 14  14  14  
Absent 15 0.147 15 0.118 15 0.121 
Lymph node metastasis       
Present 4  4  4  
Absent 9 0.322 9 0.074 9 0.232 
Rate of growth       
Slow 11  11  11  
Medium 11 0.032* 11 0.028* 11 0.021* 
Fast 7 0.041* 7 0.036* 7 0.039* 
Abbreviations: COX-2, cyclooxygenase-2; VEGF, vascular endothelial growth factor; iNOS, induc-
ible nitric oxide synthases; *P < 0.05 
 
Discussion 
It has been reported that COX-2 level has prognostic significance and is 
increased in benign and malignant canine mammary tumours (Queiroga et al., 
2010). In addition, it has been established that COX-2 expression is significantly 
higher in malignant than in benign tumours in dogs (Dore et al., 2003). However, 
COX-2 immunostaining was found to be altered in different histological types of 
benign tumours such as benign mixed tumours and tubular adenoma (Queiroga et 
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al., 2007). In the study of Queiroga et al. (2007) the expression of COX-2 was shown 
in 96% of benign tumours and in 100% of the malignant tumours, whereas ductal 
hyperplasia did not express COX-2. Similarly, in our study COX-2 expression was 
higher in malignant tumours than in benign tumours, although the difference was 
not statistically significant. This study also demonstrated that COX-2 expression 
was higher in benign and malignant tumours than in adjacent non-neoplastic 
mammary glands. 
 
Fig. 1. Quantitative real-time PCR results showing COX-2, iNOS and VEGF mRNA expression 
levels in canine mammary tissue. Bars represent expression levels normalised to beta actin as the 
housekeeping gene and relative to non-neoplastic mammary glands (NMGs). *P < 0.05 relative to 
the NMGs group; mRNA: messenger RNA; PCR: polymerase chain reaction 
 
Fig. 2. Quantitative real-time PCR results showing COX-2, iNOS and VEGF mRNA expression 
levels of histological malignancy in canine mammary tissue. Bars represent expression levels nor-
malised to beta actin as the housekeeping gene and relative to G1 group. *P < 0.05 relative to the 
G1 group. mRNA: messenger RNA; PCR: polymerase chain reaction; Grade 1 (G1), well differen-
tiated; Grade 2 (G2), moderately differentiated; Grade 3 (G3), poorly differentiated tumours 
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Fig. 3. Quantitative real-time PCR results showing COX-2, iNOS and VEGF mRNA expression 
levels of tumour size in canine mammary tissue. Bars represent expression levels normalised to 
beta actin as the housekeeping gene and relative to the T1 group. mRNA: messenger RNA;  
PCR: polymerase chain reaction 
 
COX-2 overexpression in human breast cancer and its relation to the pres-
ence of distant metastasis and poor prognosis have been reported previously 
(Denkert et al., 2003). In canine mammary tumours, it has been revealed that 
COX-2 level is associated with larger tumour size, skin ulceration, adhesion to 
skin and underlying tissue, and more aggressive histological types (Queiroga et 
al., 2005; Guimaraes et al., 2014). In the present study, COX-2 expression was 
higher in poorly differentiated than in well-differentiated tumours, suggesting 
that its higher expression might be related to the increased aggressiveness of ma-
lignant tumours. 
It has been reported that COX-2 may be associated with angiogenesis be-
cause of the reduced adhesion of tumour cells to the extracellular matrix, angio-
genesis and progress of metastasis in human breast cancer (Costa et al., 2002). 
Several studies have shown that overexpression of COX-2 in tumour tissue is 
correlated with VEGF expression and microvessel density, and is a factor in-
volved in the aggressiveness of canine malignant mammary tumours (Heller et 
al., 2005; Queiroga et al., 2011). The present study has confirmed the results of 
Queiroga et al. (2011) that COX-2 and VEGF may be related to the increased 
aggressiveness of malignant tumours. The histological tumour grade is associ-
ated with the prognosis, whereas high-grade tumours are connected with low 
overall survival time in canine mammary carcinoma (Perez Alenza et al., 1997; 
Karayannopoulou et al., 2005). Our study has revealed that the histological grade 
is related to the expression of iNOS, COX-2 and VEGF. 
Tascene et al. (2012) reported that serum nitric oxide level in dogs with 
mammary tumours is significantly higher than in healthy dogs. Recent studies 
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have shown that iNOS expression in human colorectal and gallbladder cancer is 
associated with increased disease-specific fatality and/or malignancy degree (Niu 
et al., 2004; Zafirellis et al., 2010). Moreover, it has also been determined that 
iNOS expression is related to different stages of human breast carcinoma (Ran-
ganathan et al., 2016). Our study is the first to determine the expression of iNOS 
by qRT-PCR analysis in malignant mammary tumours in dogs, and the findings 
of this work show that the expression of iNOS depends on tumour grade. 
Perez Alenza et al. (1997) reported that dogs with larger tumours had short 
disease-free survival (DFS) and overall survival (OS). In addition, Philibert et al. 
(2003) found a significant difference in survival time depending on the size of 
canine mammary tumours, and dogs with tumours larger than 3 cm had a signifi-
cantly shorter survival than dogs with tumours smaller than 3 cm. Additionally, 
Ferreira et al. (2009) revealed that larger tumours were mostly malignant and 
survival time was shorter in female dogs. It is known that increase in tumour size 
is not only associated with malignancy but also with metastasis to lymph nodes 
(Sorenmo et al., 2000). Moreover, Queiroga et al. (2011) reported that tumour 
size was not associated with COX-2 and VEGF expression in canine malignant 
mammary tumours. Similarly, there was no statistically significant association 
between iNOS, COX-2 and VEGF mRNA expression levels and tumour size in 
our study. 
Karayannopoulou et al. (2005) found that the predictive value of histologi-
cal grading of canine mammary carcinomas was associated with prognosis and that 
histological grading might be useful in managing post-surgical treatment. The re-
sults of our study revealed that iNOS, COX-2 and VEGF are overexpressed in 
canine mammary tumours compared to adjacent non-neoplastic mammary 
glands, and this may contribute to the increased aggressiveness of malignant tu-
mours. 
In conclusion, the higher expression of iNOS, COX-2 and VEGF mRNA 
levels in malignant tumours and the tendency of increase in these levels (particu-
larly in grade 3 tumours) suggest that these parameters are involved in inducing 
aggressiveness in canine mammary tumours.  
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